Clinical Trial Update: Rifaximin Prophylaxis for Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome in Cirrhotic Patients [Phase 2]

View source ↗

Summary

Phase 2 trial update on rifaximin prophylaxis for spontaneous bacterial peritonitis and hepatorenal syndrome in cirrhotic patients with ascites infection.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ascites
• Cirrhosis
• Hepatorenal Syndrome
• Spontaneous Bacterial Peritonitis

Drugs mentioned

• Rifaximin (rifaximin)

Snippet

Sponsor: Samar Atef Sebaweh Mohammed | Conditions: Ascites Infection | Phase 2 | Status: COMPLETED